Chen Min, Bi Zhuajin, Kang Wenzhong, Liu Ruihan, Hongbo Liu, Jiang Yan, Wang Qun
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiangya School of Medicine, Central South University, Changsha, China.
Front Neurol. 2025 Apr 28;16:1550023. doi: 10.3389/fneur.2025.1550023. eCollection 2025.
Temporal lobe epilepsy (TLE) is a significant clinical phenotype of anti-glutamic acid decarboxylase (GAD)-associated disease, which is characterized by disturbances in GABAergic inhibitory neurotransmission. Efgartigimod, a neonatal crystallizable fragment receptor antagonist, controls the trafficking and recycling of pathogenic anti-GAD immunoglobulin G, showing promise as a therapeutic target.
We present a case report involving the treatment of three patients affected by GAD-seropositive autoimmune encephalitis with efgartigimod. The patients' overall disability was assessed using the modified Rankin scale.
After 4 weeks of efgartigimod treatment, the patients demonstrated substantial improvements, including no dementia or behavioral abnormalities and well-controlled seizures.
Our findings suggest that efgartigimod is a potential candidate drug for the treatment of anti-GADassociated autoimmune encephalitis, particularly in patients presenting with TLE.
颞叶癫痫（TLE）是抗谷氨酸脱羧酶（GAD）相关疾病的一种重要临床表型，其特征是γ-氨基丁酸（GABA）能抑制性神经传递紊乱。艾加莫德是一种新生儿可结晶片段受体拮抗剂，可控制致病性抗GAD免疫球蛋白G的转运和再循环，显示出作为治疗靶点的潜力。
我们报告一例使用艾加莫德治疗3例GAD血清阳性自身免疫性脑炎患者的病例。使用改良Rankin量表评估患者的整体残疾情况。
艾加莫德治疗4周后，患者有显著改善，包括无痴呆或行为异常，癫痫得到良好控制。
我们的研究结果表明，艾加莫德是治疗抗GAD相关自身免疫性脑炎的潜在候选药物，尤其是对伴有TLE的患者。
